Results 81 to 90 of about 1,186,479 (304)

Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society [PDF]

, 2009
Background: No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices.
Boeck, Stefan, Bruns, Christiane J., Heinemann, Volker, Jauch, Karl-Walter, Sargent, Mirja, Schäfer, Claus, Seufferlein, Thomas   +6 more
core   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Multiple pathways of plasmid DNA transfer in Helicobacter pylori [PDF]

, 2012
Many Helicobacter pylori (Hp) strains carry cryptic plasmids of different size and gene content, the function of which is not well understood. A subgroup of these plasmids (e.g.
Benghezal, Mohammed, Fischer, Wolfgang, Haas, Rainer, Holsten, Lea, Rohrer, Stefanie, Weiss, Evelyn   +5 more
core   +3 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

A kinematic study of Open Clusters: implications for their origin

, 2010
The Galactic population of open clusters provides an insight into star formation in the Galaxy. The open cluster catalogue by Dias et al.(2002b) is a rich source of data, including kinematic information.
Allen, Binney, Binney, Bovy, Carraro, Carraro, Comerón, D. Vande Putte, Danly, De La Fuente Marcos, De La Fuente Marcos, Dehnen, Dias, Dias, Dias, Durgapal, Elmegreen, ESA, Fellhauer, Fellhauer, Finch, Friel, Friel, Frinchaboy, Fu, Hernquist, Høg, I. Ferreras, Johnson, Karttunen, Kharchenko, Kharchenko, Kharchenko, Lasker, Law, Levy, Loktin, Lépine, MacMinn, Magrini, Mark Cropper, Martos, Mermilliod, Mermilliod, Miyamoto, Monet, Paunzen, Perryman, Pfalzner, Piskunov, R. P. Mignani, Roeser, Schlegel, Schönrich, Sparke, T. P. Garnier, Twarog, Van Leeuwen, Vande Putte, Vande Putte, Wakker, Wallin, Wu, Yong, Zacharias, Zacharias   +65 more
core   +1 more source

FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]

, 2004
Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Haferlach, Torsten, Hiddemann, Wolfgang, Kern, Wolfgang, Schnittger, Susanne, Schoch, Claudia   +4 more
core   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Polymer dynamics in time-dependent periodic potentials

, 2008
Dynamics of a discrete polymer in time-dependent external potentials is studied with the master equation approach. We consider both stochastic and deterministic switching mechanisms for the potential states and give the essential equations for computing ...
Kauttonen, Janne, Merikoski, Juha, Pulkkinen, Otto   +2 more
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source